Trial Profile

Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ancrod (Primary) ; Ancrod (Primary)
Indications Sensorineural hearing loss; Sudden hearing loss
Focus Therapeutic Use

Most Recent Events

01 Aug 2023 Primary endpoint Change in PTA (pure tone audiogram) in the affected ear) has not been met according to results published in the European Archives of Oto-Rhino-Laryngology
01 Aug 2023 Status changed from completed to discontinued according to results published in the European Archives of Oto-Rhino-Laryngology.
01 Aug 2023 Results published in the European Archives of Oto-Rhino-Laryngology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com